ACM
GHDX

AlphaCrest Capital Management’s Genomic Health, Inc. GHDX Stock Holding History

AlphaCrest Capital Management’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,400
Closed -$256K – 1390
2019
Q2 		$256K Sell
4,400
-8,700
-66% -$515K 0.02% 906
2019
Q1 		$918K Buy
+13,100
New +$971K 0.14% 219

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

AlphaCrest Capital Management's GHDX Position: Q3 2019 in Review

AlphaCrest Capital Management sold out of Genomic Health, Inc. (GHDX) in Q3 2019, closing a stake of 4,400 shares — an estimated $256K sold.

AlphaCrest Capital Management first reported a position in GHDX in Q1 2019 and held it in 2 quarters. The position peaked at $918K in Q1 2019. 221 funds tracked by Wall St. Rank hold GHDX as of Q3 2019.

  • AlphaCrest Capital Management reported no remaining Genomic Health, Inc. position as of Q3 2019 after selling out during the quarter.
  • AlphaCrest Capital Management sold 4,400 Genomic Health, Inc. shares in Q3 2019, an estimated $256K.
  • AlphaCrest Capital Management first reported a position in Genomic Health, Inc. in Q1 2019 and held it in 2 quarters.
  • AlphaCrest Capital Management's Genomic Health, Inc. position peaked at $918K in Q1 2019.
  • 221 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2019.

Based on AlphaCrest Capital Management's 13F filing for Q3 2019, filed 12 Nov 2019.